Nanoalum particles containing a pegylated lipid sizing agent
Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle ranges from about 1 nm to 450 nm. Such a nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.
1. A nanoalum particle comprising:
an aluminum salt; and
a sizing agent comprises a PEG linked to a lipid;
wherein a size of the nanoalum particle ranges from about 1 nm to about 450 nm, wherein the size of the particles is the Z-average as determined by dynamic light scattering, and wherein a weight ratio of the aluminum salt to the sizing agent is about 1:1-1:3, wherein the nanoalum particle is in a liquid formulation which is filter-sterilized.
2. The nanoalum particle of claim 1 , wherein the aluminum salt is selected from the group consisting of aluminum hydroxide, AlPO 4 , AlO(OH), Al(OH)(PO 4 ), and KAl(SO 4 ) 2 .
3. The nanoalum particle of claim 1 , wherein the sizing agent is PEG linked to a phospholipid.
4. The nanoalum particle of claim 3 , wherein the phospholipid is selected from the group consisting of DSPE, DPPE, DMPE, and DLPE.
5. The nanoalum particle of claim 1 , wherein an average molecular weight of the PEG ranges from about 750 Daltons to about 5000 Daltons.
6. The nanoalum particle of claim 5 , herein the average molecular weight of the PEG is about 2000 Daltons or about 5000 Daltons and the lipid is selected from the group comprising DSPE and DPPE.
7. The nanoalum particle of claim 1 , wherein the nanoalum particle is stable:
in a liquid formulation at about 0° C. to about 8° C. for about 1 month;
after repeated freeze-thaw cycles; or
in a liquid formulation at about 37° C. for about 1 month.
8. The nanoalum particle of claim 1 , wherein an average molecular weight of the PEG is about 2000 Daltons, the lipid is DSPE, and the nanoalum particle is stable in a liquid formulation at about 60° C. for about two weeks.
9. The nanoalum particle of claim 1 , wherein the size of the nanoalum particle ranges from about 300 nm to about 400 nm, an average molecular weight of the PEG is about 5000 Daltons, and the weight ratio of the aluminum salt to the sizing agent is about 1:1.
10. The nanoalum particle of claim 1 , wherein the size of the nanoalum particle is about 100 nm, an average molecular weight of the PEG is about 5000 Daltons, and the weight ratio of the aluminum salt to the sizing agent is about 1:1.5.
11. The nanoalum particle of claim 1 , wherein the size of the nanoalum particle ranges from about 70 nm to about 80 nm, an average molecular weight of the PEG is about 5000 Daltons, and the weight ratio of the aluminum salt to the sizing agent is about 1:2.
12. A method of making the nanoalum particle of claim 1 comprising:
subjecting the aluminum salt to a high energy source in the presence of the sizing agent; or
subjecting the aluminum salt to a high energy source to produce the nanoalum particle with the size ranging from about 1 nm to about 450 nm and mixing the sizing agent with the nanoalum particle within about 30 minutes after subjecting the aluminum salt to the high energy source.
13. The method of claim 12 , wherein the high energy source is at least one of a microfluidizer, an extruder, a sonicator, a high shear mixer, or a homogenizer.
14. The method of claim 12 , wherein subjecting the aluminum salt to the high energy source comprises 1 to 10 passes through the high energy source.
15. The method of claim 12 , wherein the high energy source is a microfluidizer and the mixture comprising the aluminum salt alone or in the presence of the sizing agent is passed through the microfluidizer about 10 passes.
16. A composition comprising the nanoalum particle of claim 1 and a bioactive agent.
17. The composition of claim 16 , wherein more than about 75% of the bioactive agent is associated with the nanoalum particle in the composition as determined by gel electrophoresis.
18. The composition of claim 16 , wherein the bioactive agent is a polypeptide, a fusion protein, a full-length protein, a peptide, a peptide mimetic, a polynucleotide, an antigen, a Rig-I agonist, ID97, an adjuvant, a diagnostic agent, a therapeutic agent, or an organism.
19. The composition of claim 16 , wherein the composition further comprises an adjuvant selected from the group consisting of a AS-2, monophosphoryl lipid A, 3-de-O-acylated monophosphoryl lipid A, IFA, QS21, CWS, TOM, AGPs, CpG-containing oligonucleotides, Toll-like receptor (TLR) agonists, Leif, saponins, saponin mimetics, biological and synthetic lipid A, imiquimod, gardiquimod, resiquimod, polyI:C, flagellin, GLA, SLA, STING, and combinations thereof.
20. A method of stimulating an immune response in a subject comprising administering the composition of claim 16 , to a subject, thereby stimulating an immune response in the subject.
21. The method of claim 20 , wherein the immune response is primarily a TH1 immune response, primarily a TH2 immune response, or both a TH1 and a TH2 immune response or the immune response involves activation of B-cells, activation of T cells, production of antibodies, or release of cytokines.
22. A method of delivering a bioactive agent to a cell in a subject comprising administering to the subject a composition comprising (a) the nanoalum particle of claim 1 and (b) a bioactive agent, thereby delivering the bioactive agent to the cell in the subject.
23. A nanoalum particle comprising:
an aluminum salt; and
a sizing agent comprises a PEG linked to a lipid, wherein an average molecular weight of the PEG ranges from about 750 Daltons to about 5000 Daltons;
wherein a size of the nanoalum particle ranges from about 1 nm to about 450 nm, wherein the size of the particles is the Z-average as determined by dynamic light scattering, and wherein a weight ratio of the aluminum salt to the sizing agent is about 1:1-1:3.